Expansion Opportunity TheraPanacea has expanded facilities to Milan, Italy, signaling ongoing geographic growth and potential for new hospital partnerships in Southern Europe. Sales teams can target European cancer centers and radiotherapy clinics adjacent to Milan for ART-Plan adoption and clinical workflow integration.

Clinical Collaboration With ART-Plan powering care at over 60 cancer centers across multiple regions, there is a demonstrated appetite for AI-driven radiotherapy solutions and radiomics collaborations. Prospects include expanding network partnerships, joint research studies, and multi-center deployment opportunities.

Regulatory Ready ART-Omics platform supports AI-based biomarker discovery integrated into clinical trials as certified medical devices, indicating readiness for pharma and CRO collaborations seeking scalable AI-enabled trial acceleration and regulatory-aligned workflows.

Clinical Validation Recent ESTRO activity with 16 abstracts accepted for presentation underscores strong clinical validation and visibility. This creates traction for sales pitches centered on evidence-based outcomes, decision-maker buy-in, and conference-driven lead generation.

Scale and Service Network As a University Paris-Saclay spin-off with healthcare facility partnerships and a mid-sized team, TheraPanacea offers a balance of cutting-edge AI capability and hands-on implementation support. Opportunities exist to upsell managed services, training, and expanded installation at existing or new centers.